Drug Trial Radar · NCT07247058
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Dec 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Recordati Rare Diseases Inc
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.
Conditions
- Mild Autonomous Cortisol Secretion (MACS)
Interventions
Osilodrostat (Isturisa)Drug
The intervention aims to evaluate the impact of osilodrostat on cardiometabolic outcomes, bone mineral density, body composition, adrenal tumor size or hyperplasia, and biochemical markers of cortisol excess.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in fasting glucose, HbA1cTime frame: Baseline, and then every 3 months up to 2 years
- Change in bone mineral density (g/cm²)Time frame: Baseline, 1 year, and 2 years
- Change in body weight (kg) from baseline during Isturisa treatmentTime frame: Baseline and every 3 months up to 2 years
- Change in lipid profile from baseline during Isturisa treatmentTime frame: Baseline and every 3 months up to 2 years
- Change in body composition (kg)Time frame: baseline, 1 year and 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins University School of Medicine
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.